Multiple Myeloma Hub | Quarter One 2020 Update

The Multiple Myeloma (MM) Hub continues to disseminate the latest clinical updates in MM.

Guided by an international steering committee of world experts, and run in collaboration with the European School of Haematology (ESH), the MM Hub is a global online resource that provides vital information for treatment teams, including hematologists and oncologists. Our mission is to provide up-to-date, practical, and clinical advice to community hematologists and oncologists, and ensure patients with MM have access to the latest therapies available.

With an ever-expanding social media presence, the MM Hub engages with the global community on all major social media networks, providing a finger on the pulse of everyday, real-world clinical advances. The MM Hub showcases unbiased and credible evidence-based literature, drug approvals, case studies, international congress coverage, and expert opinions, and is delivered by Scientific Education Support (SES). SES strives to build communities and networks to enhance the level of collective knowledge, using multichannel communications to disseminate medical advances.

The MM Hub is designed to deliver upon an unmet need for targeted medical updates, to help treatment teams involved in MM care make informed therapeutic decisions. The MM Hub continue to showcase content relating to hot topics in MM via educational themes, focusing this quarter on CAR T-cell therapies and improving frontline therapies for patients with MM. Additionally, the MM Hub featured the latest clinical and translational insights gathered during the 2^nd European CAR T Cell Meeting, Sitges, ES, and Clinical Advances in Myeloma Meeting, London, UK. In addition to the written content, the MM Hub provided live social media coverage from both meetings, expert interviews, and was recognized as one of the top influencers. Last quarter, the MM Hub also restructured the steering committee, introducing Maria-Victoria Mateos as co-chair alongside Sagar Lonial, and welcoming Irene Ghobrial, Elena Zamagni, and Nina Shah to the committee.

The MM Hub would like to thank our silver supporter Janssen Oncology, bronze supporter Amgen, and contributor level supporters GSK and Karyopharm Therapeutics for their continued support.

For further information on the MM Hub, please visit multiplemyelomahub.com/. For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com.